Drug Repurposing Platform

A platform compares molecular profiles of tumors or tumor cells with information in drug-response databases. Computational matching then looks for relationships between those profiles and a compound’s known targets or mechanisms. This process can rank existing drugs whose established biological activity appears relevant to a vulnerability in a particular cancer, creating focused candidates for experimental testing.

Known targets and mechanisms provide a biological rationale for linking an established drug to a tumor-cell vulnerability. Rather than treating a computational match as evidence by itself, researchers can use this information to explain why a compound might affect cancer cells and to decide which candidates merit laboratory validation. This interpretability also helps organize candidates around shared mechanisms across tumor types.

A platform can prioritize drug combinations by connecting compound activity with molecular features associated with tumor vulnerabilities. The same matching logic can help identify biomarkers, measurable molecular features used to distinguish relevant tumor contexts, for follow-up studies. These outputs support testing whether activity is concentrated in selected tumor types or molecularly defined groups.

A promising computational match still requires evidence about efficacy, toxicity, and translational feasibility. Laboratory screening and validation in relevant cellular or animal models help determine whether the predicted activity is reproducible in biological systems and whether unwanted effects could limit development. Considering these factors before clinical testing helps distinguish an informative prediction from a practical therapeutic candidate.

The process begins with molecular profiles and drug-response databases, followed by computational matching based on known drug targets or mechanisms. Researchers then conduct laboratory screening of prioritized compounds and validate selected candidates in relevant cellular or animal models. This staged workflow narrows broad drug possibilities into candidates supported by progressively stronger evidence for cancer applications.

Relevant cellular and animal models provide experimental validation after computational matching and laboratory screening. They allow researchers to examine whether a prioritized compound shows the expected anticancer activity in a biological system and to assess efficacy and toxicity before clinical testing. Using these models helps determine whether a computationally supported candidate has sufficient evidence for further translation.

The resulting evidence can help researchers prioritize individual compounds, select candidates for combination therapy, and identify activity that may extend across tumor types. It can also support biomarker-guided studies and inform judgments about efficacy, toxicity, and translational feasibility. Together, these outputs help organize experimental programs before a candidate is considered for clinical testing.